Schizophrenia/Psychosis

Care partners for patients with schizophrenia can greatly benefit from psychoeducation provided by clinicians.

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

Dive into the forms of assessment for cognitive dysfunction in relation to the diagnosis and treatment of schizophrenia.

BioXcel Therapeutics advances BXCL501 for at-home treatment of agitation in bipolar disorders and schizophrenia, aiming for FDA approval by 2026.

Nearly half of catatonia patients relapse within two years, highlighting the need for effective long-term management strategies and potential benefits of antipsychotics.

BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.

AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions, highlighting urgent regulatory needs.

UK study of "active ingredients" in early psychosis intervention is applicable to US programs, according to the codirector of Stanford's INSPIRE Clinic.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

Extreme heat poses serious health risks, especially for vulnerable populations. Learn essential tips to help patients stay safe during heat waves and protect their well-being.

Learn more about effective strategies for managing obesity and metabolic dysfunction in schizophrenia, focusing on dietary interventions and pharmacological treatments.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

Women with schizophrenia face increased breast cancer risks linked to long-term prolactin-raising antipsychotic use, highlighting the need for regular screenings and tailored treatment strategies.

Clinicians explore the potential of xanomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Discover groundbreaking schizophrenia treatment with xanomeline-trospium, targeting cholinergic pathways for improved symptoms and fewer side effects.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.

Innovative digital therapeutics like CT-155 are transforming mental health treatment, targeting negative symptoms of schizophrenia and enhancing depression care. Check out this conversation with Shaheen Lakhan, MD, PhD.

It is critical to recognize the early signs of schizophrenia and provide timely intervention to prevent full-blown psychosis in adolescents.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.

Learn more about how to best assess and treat tardive dyskinesia.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.